P2X3 receptor antagonist (Intragrand Pharma)

P2X3 receptor antagonist (Intragrand Pharma) is a preclinical-stage small molecule being developed by Intragrand Pharma for the treatment of migraine disorders and cough. The drug acts as an antagonist of the P2X3 receptor, a trimeric ATP-gated ion channel primarily expressed on primary sensory neurons (nociceptors). Activation of P2X3 receptors by extracellular ATP is associated with the sensitization of the cough reflex and the transmission of pain signals in the trigeminovascular system. By blocking these receptors, the candidate aims to reduce neuronal hypersensitivity and alleviate symptoms of chronic cough and migraine. The asset was identified through patent mining (e.g., WO2022156753) and is part of Intragrand's pipeline focusing on sensory neuron-related pathologies.

Other names

Intragrand Pharma P2X3 receptor antagonist